Loading
Every dated change on the records linked to Localised prostate cancer, intermediate risk, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Rate ratio for prostate cancer death 0.
5-year failure-free survival 84% in both arms, non-inferior.
A milestone in how this cancer is treated.
Nine-year biochemical progression-free survival 83 percent with a low-dose-rate brachytherapy boost against 62 percent with a dose-escalated external beam boost (multivariable hazard ratio for failure 2.
All-cause mortality 61.
Five-year biochemical and clinical failure-free survival 85 percent in both arms (hazard ratio 0.
Multiparametric MRI sensitivity 93 percent against 48 percent for transrectal biopsy, at the cost of specificity (41 against 96 percent); as a triage test it would spare 27 percent of men a biopsy and find up to 18 percent more clinically significant cancers.
5-year biochemical or clinical failure-free survival 90.
Six months of androgen suppression added to radiotherapy improved biochemical disease-free survival (hazard ratio 0.
15-year prostate-cancer mortality 3.
A milestone in how this cancer is treated.